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OPEN ACCESS
Rapid diagnostic tests have the potential to reduce the overtreatment of malaria by 95%, but time
and extensive logistical, behavioural, and technical interventions may be required to achieve this,
argue Eleanor Ochodo and colleagues
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senior clinical lecturer 2
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Medical care of populations often treads a fine line between the
differing harms of underdiagnosis and overdiagnosis.
Underdiagnosis may mean that a disease is advanced by the
time it is detected, increasing the risk of death, whereas
overdiagnosis leads to healthy people being labelled as sick and
treated with drugs that will be of no benefit and may even cause
harm.1 How much underdiagnosis or overdiagnosis can be
regarded as “reasonable” is a value judgement and may vary
between different stakeholders: consumers, clinicians, or policy
makers. It will also vary between diseases and populations and
be related to the severity of the illness, the benefits and harms
of the treatment, the cost of the treatment, the availability of
reliable tests, and the public health effects of the approach taken.
Malaria is an interesting case study because the perceived
benefits of overdiagnosis (few missed cases), and the potential
harms of underdiagnosis (unpredictable progression to severe
malaria and death) led to the promotion of substantial
overdiagnosis and overtreatment for many years.2-4 Up until
about 15 years ago, policy makers, including the World Health
Organization, promoted a strategy known as “presumptive
treatment of malaria” in areas where diagnostic testing (by light
microscopy) was unavailable. This strategy recommended that
all patients with fever were treated with antimalarials, regardless
of the presence or absence of signs of other illnesses, and
accepted the substantial overuse of chloroquine because it was
cheap and well tolerated.2 3
However, the balance has now swung the other way, with policy
makers and clinicians increasingly concerned about the clinical,
financial, and public health harms associated with overtreatment.
The currently recommended firstline antimalarial drugs
(artemisinin based combination therapies) are not cheap and
malaria prevalence is falling in many countries, raising the
relative importance of diagnosing and treating other causes of
fever.4-6Consequently, the development of rapid diagnostic tests
(RDTs) that can be used in basic healthcare services in remote
settings led the WHO to recommend a switch to universal
parasitological testing before treatment in 2010.5 Despite the
subsequent rapid scale-up of rapid tests, overtreatment remains
a problem. We examine the drivers and examine the potential
strategies to overcome these.
Why might overtreatment still occur?
The figure⇓ outlines three scenarios that can result in
overtreatment of malaria, the different drivers, and possible
solutions.
Scenario 1: test not done; fever treated
presumptively
The latest WHO data show that the reported rate of diagnostic
testing in the African region increased from 41% in 2010 to
65% in 2014.6 This is impressive progress in the public sector
but does not measure the scale of the problem in the private and
retail sectors. In Uganda, around two thirds of people seek
malaria treatment from retail drug stores, where testing is rarely
done,7 and this situation seems to be replicated in other African
countries.4 In Kenya, over-the-counter malaria medicines were
shown to be the most popular first response to fever in children
and adults with acute illnesses.8
Another reason for not testing is shortage of rapid tests.
Cross-sectional studies in Tanzania,9 Mozambique,10 and
Democratic Republic of Congo11 estimated that 50%, 59%, and
62%, respectively, of the facilities surveyed did not have RDTs
in stock. Even when RDTs are available, they may not be
universally used. In one study from Tanzania staff reported
reverting to presumptive treatment when patient workload was
high or during staff shortages.9
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Scenario 2: test result is false positive
A small number of false positive results are inevitable with any
diagnostic test, but the high specificity of available RDTsmeans
this number is likely to be negligible in comparison with the
“false positives” of presumptive diagnosis.
Table 1⇓ presents the test outcomes for a hypothetical cohort
of 100 patients with fever tested with the most commonly used
RDTs in settings with different prevalences of malaria. The
sensitivity and specificity estimates are derived from
meta-analytical summaries of 71 studies included in the
Cochrane review of RDT accuracy.12
In all four settings RDTs have the potential to reduce
unnecessary prescriptions by around 95% compared with
presumptive treatment. In absolute terms this means preventing
between 19 and 90 unnecessary prescriptions per 100 people
tested. The largest number of false positive results would occur
in the settings of lowest prevalence but remain very small.
Scenario 3: test result is negative but
antimalarial drugs are still prescribed
Increased use of RDTs will be a waste of resources unless health
workers use the result to guide prescribing. In a Cochrane review
of studies that randomly assigned health workers to using RDT
based algorithms or clinical diagnosis, compliance with the
RDT result was highly variable across studies. In the most
extreme example health workers prescribed antimalarial drugs
to 81% of people with negative results.13 In trials in which health
workers adhered to the test result antimalarial prescriptions were
reduced by up to three quarters. These are early trials and we
would expect adherence to improve during programmatic use.
Several qualitative studies have explored the reasons for health
workers ignoring the test result.14-17 Commonly cited reasons
are a lack of trust in the accuracy of tests; fear of the
consequences of missing a true malaria case; confusion about
the change from previous recommendations; pressure to
prescribe from patients; and uncertainty about how to manage
the other causes of fever. Studies among patients also report a
lack of trust in the test’s accuracy, enhanced by conflicting
advice from different health facilities and feeling better after
taking antimalarial drugs even when the test result is negative.
What are the risks associated with RDTs?
Previous training and guidance to health workers emphasised
the danger of missing a case of malaria and sending a child
home without treatment.2 This ingrained belief is likely to take
time to change, and health workers will require evidence based
reassurance that this new policy is safe.
How common are false negative results?
The hypothetical cohorts in table 1⇓ indicate that the balance
of benefit and harms with RDTs is most favourable in areas
with low malarial endemicity. In settings with a pretest
probability of 5% (5% of fevers are due to malaria), using RDTs
could prevent 90 unnecessary antimalarial prescriptions per 100
people tested, with less than one true malaria case being missed.
As the pretest probability gets higher, up to 60%, the balance
is closer: with 38 unnecessary prescriptions prevented at the
cost of missing three true malaria cases: and in truly epidemic
conditions with a pretest probability of 80% there is an argument
that reverting to presumptive diagnosis would be the safest and
certainly most cost effective thing to do.
While this may be reassuring for those in low endemic settings,
concerns have been raised that clinical malaria can occur at
parasite counts below those detectable by standard RDTs and
the risk of progression to severe malaria may be higher because
of lower immunity.18 These potential risks need quantifying.
What is the risk of severe malaria developing
in people sent home without treatment?
In the Cochrane review by Odaga et al, five trials randomised
health workers to using RDT diagnosis or clinical diagnosis
(presumptive treatment). Despite large reductions in the use of
antimalarials when health workers adhered to the RDT result,
there were no clinically important differences in the number of
people remaining unwell four to seven days later.13
We also found a longitudinal study from Tanzania19 that
followed up children with negative results for two weeks after
being discharged without antimalarials. Of 1000 children with
fever who had RDTs, 603 (60%) tested negative, and it is worth
noting the average sensitivity of RDTs would predict around
20 missed cases in this setting. Over the course of the study 587
(97.3%) got better without antimalarials, three (0.5%) had
subsequent positive test results at re-attendance andwere treated,
two (0.3%) died (of sepsis and pneumonia with repeated
negative RDT results), and 12 (2%) were lost to follow-up.
This study was done in programmatic conditions close to routine
practice and may offer some reassurance that if patients with
persisting symptoms are able to return to the health post they
will, and without serious consequences. Similar studies and
local audits may help to reassure health workers further.
What strategies might be used to reduce
overtreatment?
Clearly, countries need a range of strategies across all levels of
the health system to fully implement universal testing. Table
2⇓ presents some of the approaches currently being evaluated.
Improved management could help stop RDTs becoming out of
stock, and mobile phone technology has been touted as a
potential solution. A mobile phone short messaging service
(SMS) and web based system was evaluated in rural districts
in Tanzania20 and Kenya.21 Mobile phones have also been
evaluated as a means to improve quality assurance of RDTs11
and to enable easy access to guidelines and clinical decision
aids.37 39
A subsidy on artemisinin based combination therapy had some
success in increasing its availability in the private sector, and
some have advocated for a similar approach to promote the use
of RDTs by private drug sellers.22 40 However, others argue that
the economics and effects of a subsidy are far from
straightforward.41
The effectiveness of training or education required to change
the behaviour of both health workers and patients has also been
under evaluation. Simple, short training for health workers on
using RDTs was evaluated in Cameroon,31 and more complex
training interventions including both the community and patients
have been evaluated in three arm cluster randomised trials in
Tanzania32 and Nigeria.36
Changing behaviour is rarely easy, and as well as generating
their own evidence, malaria experts should draw on the lessons
from similar efforts to reduce antibiotic prescribing in other
illnesses.28-30
In conclusion, universal testing for malaria is a major policy
shift that will take time and extensive resources to fully
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implement across sub-Saharan Africa. Success will require
different interventions across public, private, and retail sectors.
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Key messages
Universal testing for malaria will take time and extensive resources to fully implement across sub-Saharan Africa
Interventions are required to overcome logistical health system constraints and change the beliefs and behaviour of health workers and
patients
Further developments to improve the accuracy of tests are also important
Tables
Table 1| Outcomes of rapid diagnostic testing in hypothetical cohorts of 100 people presenting with fever in settings with different malaria
prevalences*
No of cases/100 people (95% CI)Pretest probability of positive
result (%) Malaria is true cause of feverNon-malarial cause of fever
False negatives¶True positives§True negatives‡False positives†
0 (0 to 0)5 (5 to 5)90 (89 to 92)5 (3 to 6)5
2 (1 to 2)29 (28 to 29)66 (65 to 67)4 (3 to 5)30
3 (2 to 4)57 (56 to 58)38 (37 to 38)2 (2 to 3)60
5 (3 to 5)76 (75 to 77)19 (19 to 19)1 (1 to 1)80
*Type 1 HRP-2 rapid diagnostic test (RDT) with average sensitivity of 94.8% (95% CI 93.1 to 96.1) and specificity 95.2% (95% CI 93.2 to 96.7).12
†Number of unnecessary prescriptions that would still occur when using RDTs (the true cause of fever may also go untreated).
‡Number of unnecessary antimalarial prescriptions that could be avoided if RDTs are used instead of presumptive treatment.
§Number of people correctly diagnosed with malaria by the RDT.
¶Number of people with malaria who would be sent home without antimalarials because of a negative RDT result.
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Table 2| Potential strategies to curb overtreatment of fever as malaria
Experimental approachesEstablished approachesProblem
Scenario 1: test not done, fever treated presumptively
Using technology such as short text messaging (SMS), internet, and
electronic mapping to track stock of RDTs 20 21
-RDT shortages
Provision of free or subsidised RDTs through the private sector22 23-Limited RDT availability in private drug
retail sector
-Use of community health workers to diagnose and
treat uncomplicated malaria24 25
Staff shortages and high patient load in
health centres
Scenario 2: test positive but the result is a false positive
Enabling external QA of reading and interpretation of RDTs by
sending test photographs via SMS11
Regular quality testing of RDTs from
manufacturers by WHO26
Low specificity of tests
Urine or fluorescent RDTs27
Scenario 3: test negative; but antimalarial drugs are still prescribed
Evidence based training on the accuracy of RDTs and safety of not
treating when results are negative31 32
Interactive educational meetings28
Multifaceted interventions including health workers,
patients and the public 28 29 30
Uncertainty about RDT accuracy and
perceived risk of mortality in people with
false negatives results
Electronic or mobile friendly guidelines34Accessible formats for guidelines, e.g. summaries33
Improving referral paths for patients with negative results35Integrated case management of malarial and
non-malarial causes of fever24 25
Uncertainty about how to manage fever
when test is negative
Incorporating patient communication skills in training packages of
health workers32 36
Mass media interventions38Expectation that patients will seek
treatment elsewhere
Use of clinic posters, decision aids and patient pamphlets and
community awareness programmes32 36
SMS reminders reiterating the treatment advice based on RDT result37
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Figure
Fig 1 Logic framework of scenarios and drivers of overtreatment despite rapid diagnostic tests (RDTs) with potential
interventions
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